Fundraising Fox
🦊/Companies
Sign in

Poseida Therapeutics

San Diego, US · Founded 2014 · Delaware corporation · 18,294 employees on LinkedIn · 4 known investors

Find your way into Poseida Therapeutics

Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.

BiotechHealthtech

Founders & leadership

Poseida Therapeutics was founded in 2014 by Eric Ostertag.

EOEric Ostertag
Eric OstertagFounder
MGMark Gergen
Mark GergenExecutive

Board

AH
Adrian HowdBoard director
DH
David HirschBoard director

Investors · 4

Aisling CapitalNew York
Longitude CapitalMenlo Park · $10M – $30M
Rapha Capital Management, LLCSurfsidevia Kevin M. Slawin · inferred
Vivo CapitalreportedPalo Alto · $10M – $50M

Funding

SEC filings, press & company announcements

$231.8M disclosed across 5 of 7 rounds · 2015–2023

▶$25MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Harry J. LeonhardtExecutive Officer
  • Mark J. GergenExecutive Officer, Director
  • Johanna M. MyletExecutive Officer
  • Luke CorningDirector
  • Cynthia CollinsDirector
  • Marcea B. LloydDirector
  • Brent WarnerExecutive Officer
  • Charles M. BaumDirector
  • Kristin YaremaExecutive Officer
  • John SchmidDirector
  • Rafael AmadoDirector
Offering amount
$25M
Amount sold
$25M
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$142.1MraisedApr 2019 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John SchmidDirector
  • Noah BerkowitzDirector
  • Marcea Bland LloydDirector
  • Eric OstertagExecutive Officer, Director
  • David HirschDirector
  • Catherine J. MackeyDirector
  • Sean MurphyDirector
  • Mark GergenExecutive Officer, Director
  • Matthew SpearExecutive Officer
Offering amount
$150M
Amount sold
$142.1M
First sale
Mar 2019
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.5MraisedApr 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adrian HowdDirector
  • Eric OstertagExecutive Officer, Director
  • Mark GergenExecutive Officer, Director
  • David HirschDirector
Offering amount
$30.5M
Amount sold
$30.5M
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.2MraisedAug 2017 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adrian HowdDirector
  • Eric OstertagExecutive Officer, Director
  • Robert LyonsDirector
  • Lars EkmanDirector
  • Nishan de SilvaExecutive Officer, Director
Offering amount
$15M
Amount sold
$11.2M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23MraisedDec 2015 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric OstertagExecutive Officer, Director
  • Nishan de SilvaExecutive Officer, Director
  • Lars EkmanDirector
Offering amount
$36M
Amount sold
$23M
First sale
Dec 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Poseida Therapeutics stock (US74020J1025): cash-and-stock merger puts gene therapy player in focusad-hoc-news.de · May 2026Poseida Therapeutics stock (US74020J1025): FDA setback puts spotlight on its cancer pipelinead-hoc-news.de · May 2026Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023prnewswire.com · Nov 2023Oncology biotech Poseida Therapeutics raises proposed deal size by 49% ahead of $224 million IPO | Nasdaqnasdaq.com · Jul 2020Poseida Therapeutics Raises $110 Million in Series D Financingprnewswire.com · Jun 2020Poseida Therapeutics guns again for IPO | Fierce Biotechfiercebiotech.com · Jun 2020Poseida Therapeutics, Inc. - Rapha Capital Management, LLCraphacap.com · Apr 2020Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies - MedCity Newsmedcitynews.com · Apr 2019

Frequently asked questions

What does Poseida Therapeutics do?
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications. The company was acquired by Roche, with its programs now developed by Genentech.
Who founded Poseida Therapeutics?
Poseida Therapeutics was founded by Eric Ostertag in 2014.
Who are Poseida Therapeutics's investors?
Poseida Therapeutics's investors include Aisling Capital, Longitude Capital, Rapha Capital Management, LLC, Vivo Capital.
How much funding has Poseida Therapeutics raised?
Poseida Therapeutics has disclosed $231.8M raised across 5 of its 7 known rounds.
Where is Poseida Therapeutics headquartered?
Poseida Therapeutics is headquartered in San Diego, US.